Clinical Trials Sponsored by ViaCell

Total 75 results

ViaCell

Withdrawn

Safety and Efficacy of Freezing and Thawing of Human Eggs in Assisted Reproductive Technology

Infertility

United States
ViaCell

Completed

Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers

Acute Myeloid Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Chronic Myelogenous Leukemia

United States
Vivacelle Bio

Active, not recruiting

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

Sepsis | Septic Shock | Hypovolemia

United States
Vivacelle Bio

Not yet recruiting

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients (VBI-S-02) (VBI-S-02)

Sepsis | Septic Shock | Hypovolemia
Micell Technologies

Completed

First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease (DESSOLVE-I)

Coronary Artery Disease

Belgium, Australia, New Zealand
Gracell Biotechnologies Ltd.

Recruiting

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
BriaCell Therapeutics Corporation

Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC)

Breast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage Cancer

United States
Micell Technologies

Completed

Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease (DESSOLVE-II)

Coronary Artery Disease

New Zealand, Netherlands, United Kingdom, France, Belgium, Sweden
Gracell Biopharmaceuticals, Inc.

Recruiting

A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

United States
Vaxcell Bio, Co., Ltd.

Recruiting

Natural Killer (NK) Cell Therapy in Locally Advanced HCC

Locally Advanced Hepatocellular Carcinoma

Korea, Republic of
BriaCell Therapeutics Corporation
LumaBridge

Enrolling by invitation

Combination Study of SV-BR-1-GM With Retifanlimab

Breast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic

United States
Xijing Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Peking University
Gracell Biopharmaceuticals, Inc.

Recruiting

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
BriaCell Therapeutics Corporation
Cancer Insight, LLC

Completed

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Breast Neoplasm | Breastcancer

United States
RenJi Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

CAR-T Cell Therapy

China
Zhejiang University
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

CAR-T

China
Peking University Third Hospital
Gracell Biotechnology Ltd.

Not yet recruiting

A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Completed

A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China
Shanghai Tong Ren Hospital
Gracell Biotechnology Ltd.

Unknown

CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

B-cell Lymphoma | B-cell Malignancy | B-Cell Acute Lymphoblastic Leukaemia

China
ECRI bv
Micell Technologies; Stentys

Completed

Study Comparing the MiStent SES Versus the XIENCE EES Stent (DESSOLVE III)

Coronary Stenosis

France, Germany, Netherlands, Poland
Shanghai IxCell Biotechnology Co., LTD

Not yet recruiting

Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke

Ischemic Stroke
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Eden BioCell Ltd.
National Taiwan University Hospital

Terminated

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

Taiwan
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Multiple Myeloma

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

B-cell Non Hodgkin Lymphoma

China
Micell Technologies
Cardialysis BV; ClinLogix. LLC

Unknown

Trial of MiStent Compared to Xience in Japan (DESSOLVEJ)

Coronary (Artery); Disease

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH); ViaCell

Completed

Cord Blood Expansion on Mesenchymal Stem Cells

Leukemia | Myelodysplastic Syndrome

United States
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Study of FasT CAR-T GC012F Injection NDMM Patients

Multiple Myeloma

China
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

Multiple Myeloma

China
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Multiple Myeloma

China
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Unknown

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Multiple Myeloma

China
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Multiple Myeloma

China
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Shanghai iCELL Biotechnology Co., Ltd, Shanghai...

Not yet recruiting

Safety and Efficacy Study of hAESCs Therapy for aGVHD (aGVHD，hAESCs)

GVHD,Acute
iCell Gene Therapeutics
iCar Bio Therapeutics

Recruiting

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Relapsed/Refractory, High Risk Hematologic Malignancies | T-ALL/Lymphoma

China
Huda Salman
iCell Gene Therapeutics

Recruiting

CD4CAR for CD4+ Leukemia and Lymphoma

T-cell Lymphoma | T-cell Leukemia

United States
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.; Beijing Lu Daopei Hospital

Unknown

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China
iCell Gene Therapeutics
iCAR Bio Therapeutics Ltd. China

Recruiting

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)

China
Shanghai East Hospital
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Unknown

Treatment of Nonunion of Limb Fracture With Human Amniotic Epithelial Cells（hAECs）

Nonunion Fracture

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Shanghai East Hospital
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Not yet recruiting

Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.

Parkinson's Disease

China
Shanghai East Hospital
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Recruiting

Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson's Disease

Idiopathic Parkinson's Disease

China
Shanghai East Hospital
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Completed

Stereotactic Transplantation of hAESCs for Parkinson's Disease

Parkinson's Disease

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Refractory T-Cell Lymphoma | T Cell Lymphoma in Relapse

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Plasmacytoid; Lymphoma

China
Peking University People's Hospital
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Unknown

hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation

Leukemia

China
Peking University People's Hospital
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Unknown

Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation (hAECs-GVHD)

Acute-graft-versus-host Disease

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (CD5CAR-T)

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma

China
Shanghai iCELL Biotechnology Co., Ltd, Shanghai...
Hebei Yanda Ludaopei Hospital

Unknown

Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease

Acute Myeloid Leukemia

China

Clinical Trials Sponsored by ViaCell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations